{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Urothelial+Cancer&page=2",
    "query": {
      "condition": "Advanced Urothelial Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Urothelial+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T06:05:13.765Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03601455",
      "title": "Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Urothelial Carcinoma",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IVA Bladder Cancer AJCC v8",
        "Stage IVB Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2018-10-26",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-07-22T06:05:13.765Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03601455"
    },
    {
      "nct_id": "NCT03894618",
      "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck",
        "Melanoma",
        "Non Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Squamous Cell Carcinoma of the Anus",
        "Squamous Cell Carcinoma of the Cervix",
        "Squamous Cell Carcinoma of the Skin",
        "Renal Cell Carcinoma",
        "Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Mismatch Repair Deficient or MSI-High Solid Tumors"
      ],
      "interventions": [
        {
          "name": "SL-279252",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shattuck Labs, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2019-03-26",
      "completion_date": "2023-05-04",
      "has_results": true,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-07-22T06:05:13.765Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03894618"
    },
    {
      "nct_id": "NCT06285097",
      "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Non-small-cell Lung Cancer",
        "Melanoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Renal Cell Carcinoma",
        "Urothelial Carcinoma",
        "Colorectal Carcinoma",
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-07820435",
          "type": "DRUG"
        },
        {
          "name": "Sasanlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2024-02-08",
      "completion_date": "2025-02-13",
      "has_results": false,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-07-22T06:05:13.765Z",
      "location_count": 6,
      "location_summary": "Sarasota, Florida • Grand Rapids, Michigan • Nashville, Tennessee",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06285097"
    },
    {
      "nct_id": "NCT03821935",
      "title": "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors Cancer"
      ],
      "interventions": [
        {
          "name": "Livmoniplimab",
          "type": "DRUG"
        },
        {
          "name": "Budigalimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 364,
      "start_date": "2019-02-21",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-07-22T06:05:13.765Z",
      "location_count": 21,
      "location_summary": "Springdale, Arkansas • Duarte, California • Irvine, California + 16 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03821935"
    },
    {
      "nct_id": "NCT06034860",
      "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Hepatocellular Carcinoma",
        "Melanoma",
        "Renal Cell Carcinoma",
        "Microsatellite Instability High",
        "Mismatch Repair Deficiency",
        "Mesothelioma",
        "Esophageal Squamous Cell Carcinoma",
        "Squamous Cell Carcinoma of Head and Neck",
        "Urothelial Carcinoma",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "MT-8421",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular Templates, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2023-11-01",
      "completion_date": "2024-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-11-01",
      "last_synced_at": "2026-07-22T06:05:13.765Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06034860"
    },
    {
      "nct_id": "NCT04879329",
      "title": "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "disitamab vedotin",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 372,
      "start_date": "2022-05-03",
      "completion_date": "2029-04-14",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-07-22T06:05:13.765Z",
      "location_count": 159,
      "location_summary": "Gilbert, Arizona • Anaheim, California • Arcadia, California + 96 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04879329"
    },
    {
      "nct_id": "NCT05941507",
      "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "LCB84",
          "type": "DRUG"
        },
        {
          "name": "Anti-PD-1 monoclonal antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LigaChem Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2023-10-05",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-24",
      "last_synced_at": "2026-07-22T06:05:13.765Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05941507"
    },
    {
      "nct_id": "NCT02887248",
      "title": "Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Bladder Cancer",
        "Transitional Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-01-12",
      "completion_date": "2020-05-01",
      "has_results": true,
      "last_update_posted_date": "2023-12-05",
      "last_synced_at": "2026-07-22T06:05:13.765Z",
      "location_count": 5,
      "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 2 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02887248"
    },
    {
      "nct_id": "NCT00055835",
      "title": "S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Urethral Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "neoadjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2002-11",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-07-22T06:05:13.765Z",
      "location_count": 92,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00055835"
    },
    {
      "nct_id": "NCT04953104",
      "title": "ARID1A and/or KDM6A Mutation and CXCL13 Expression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Bladder Urothelial Carcinoma",
        "Locally Advanced Renal Pelvis Urothelial Carcinoma",
        "Locally Advanced Ureter Urothelial Carcinoma",
        "Locally Advanced Urethral Urothelial Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Renal Pelvis Urothelial Carcinoma",
        "Metastatic Ureter Urothelial Carcinoma",
        "Metastatic Urethral Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Recurrent Bladder Urothelial Carcinoma",
        "Recurrent Renal Pelvis Urothelial Carcinoma",
        "Recurrent Ureter Urothelial Carcinoma",
        "Recurrent Urethral Urothelial Carcinoma",
        "Recurrent Urothelial Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Stage IIIB Bladder Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Renal Pelvis Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8",
        "Stage IVA Bladder Cancer AJCC v8",
        "Stage IVB Bladder Cancer AJCC v8",
        "Unresectable Bladder Urothelial Carcinoma",
        "Unresectable Renal Pelvis Urothelial Carcinoma",
        "Unresectable Ureter Urothelial Carcinoma",
        "Unresectable Urethral Urothelial Carcinoma",
        "Unresectable Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Diagnostic Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Relatlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-09-21",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-07-22T06:05:13.765Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04953104"
    }
  ]
}